louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04643184: Follow-up Strategies for Fragile Patients With Decompensated Heart Failure
Official title: Clinical Trial on Follow-up Strategies for Fragile Patients With Decompensated Heart Failure
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Heart Failure; With Decompensation
Fragility
Lead sponsor: Hospital Italiano de Buenos Aires
Sponsor class: OTHER
First posted: 2020-11-25
Enrollment: 37
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Co-management program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Randomized controlled clinical trial with intervention branch (management program cardiological-geriatric) and control branch (usual care) for fragile patients with decompensated heart failure.

Detailed description: Randomized controlled clinical trial with intervention branch (management program cardiological-geriatric) and control branch (usual care) for fragile patients with decompensated heart failure. Follow-up period 1 month.

This protocol aims through a multidisciplinary vision, to carry out during hospitalization a comprehensive geriatric evaluation that allows to know the medical and socio-environmental needs of the patient to plan the required care at home and achieve an effective transition.

Eligibility criteria: Inclusion Criteria:

1. Age 65 years or older
2. Decompensated heart failure
3. FRAIL scale equal to 3 or more points
4. Permanent residence in the Metropolitan Area of Buenos Aires

Exclusion Criteria:

1. Refusal to participate in the study
2. Terminal oncology or cardiological disease
3. Reversible or treatable etiology heart failure (e.g. Takotsubo, acute cardiomyocarditis)
4. Patients followed by geriatrics prior to admission
5. Simultaneous participation in another research protocol

Primary outcomes:
measure: Hospital admission
timeFrame: 30 days
Secondary outcomes:
measure: Mortality
timeFrame: 30 days
Other outcomes:
measure: Prevalence of fragility
timeFrame: Admission
Locations:
city: Buenos Aires
country: Argentina
facility: Rodrigo Aguirre
state: C.a.b.a
Study officials:
affiliation: Hospital Italiano de Buenos Aires
name: César Belziti, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01022684: Correlation Between Various Inflammatory Markers and Vascular Inflammation Measured by 18FDG-PET
Official title: Correlation of Inflammatory Markers Such as LpPLA2,MCP-1 and hsCRP for Predicting Vascular Inflammation; Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atherosclerosis
Keywords: atherosclerosis
vascular inflammation
LpPLA2
hsCRP
MCP-1
18FDG-PET
Lead sponsor: Korea University
Sponsor class: OTHER
First posted: 2009-12-01
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 88
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy participatin who underwent a medical health check in the health promotion center in Korea Guro University

Brief summary: Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. Various inflammatory markers such as LpPLA2,MCP-2 and hsCRP are well-known prognostic factors for the cardiovascular event.

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between various inflammatory markers and vascular inflammation detected by 18FDG-PET.


Eligibility criteria: Inclusion Criteria:

* Healthy patients for visiting routine medical check in our clinic

Exclusion Criteria:

* History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
* Diabetes
* Stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
* Malignancy
* Severe renal or hepatic disease
* Subjects taking medications that might affect inflammation such as NSIAD and statin

Primary outcomes:
measure: Correlation between various inflammatory markers including LpPLA2,MCP-1 and hsCRP and vascular inflammation analyzed by 18FDG-PET
timeFrame: 12 weeks
Secondary outcomes:
measure: Correlation between various inflammatory markers and atherosclerosis measured by carotid intima media thickness
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hye Jin Yoo
Study officials:
affiliation: Korea University
name: Kyung Mook Choi, MD.PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yang SJ, Kim S, Choi HY, Kim TN, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. High-sensitivity C-reactive protein in the low- and intermediate-Framingham risk score groups: analysis with 18F-fluorodeoxyglucose positron emission tomography. Int J Cardiol. 2013 Mar 10;163(3):277-281. doi: 10.1016/j.ijcard.2011.06.054. Epub 2011 Jun 29.
Clinical trial NCT01018784: A Study of MORAb-009 in Patients With Solid Tumor
Official title: A Phase 1 Study of MORAb-009 in Patients With Solid Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Mesothelin-positive
Keywords: Cancer
Mesothelin-positive
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2009-11-25
Enrollment: 17
Sex: ALL
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.


Eligibility criteria: Inclusion criteria;

1. Japanese male and female patients aged from 20 to less than 80 years at obtaining informed consent
2. Patient with histologically or cytologically diagnosed solid tumor
3. Patient who is mesothelin-positive confirmed by immunohistochemistry (IHC) (except for pancreatic cancer and mesothelioma that mesothelin-positive is frequently reported)
4. Patient with solid tumor who is non responder to or resistant to standard therapy and has no other appropriate treatment
5. Performance Status (PS) is 0 to 1 by Eastern Cooperative Oncology Group ECOG criteria

Exclusion criteria

1. Brain metastasis presenting clinical symptoms or requiring medical treatment
2. Serious and systemic infection requiring medical treatment
3. History of hypersensitivity to protein formulations including monoclonal antibody
4. With active multiple carcinoma (except for carcinoma in situ and intramucosal carcinoma)
5. With celomic fluid (pleural effusion or ascites) uncontrolled by drainage, or with a large volume of celomic fluid

Primary outcomes:
measure: To investigate dose-limiting toxicity and estimate maximum tolerated dose.
timeFrame: 4 Weeks
Secondary outcomes:
measure: The best overall response rate in the RECIST evaluation and the preliminary evaluation calculating the frequency of Completed response and Partial Response.
timeFrame: During Study
Other outcomes:
Locations:
city: Sayama-shi
country: Japan
state: Osaka
Study officials:
affiliation: Morphotek Clinical Development Section, JAC PCU
name: Chifumi Kitamura
role: STUDY_DIRECTOR
References:
citation: Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8. doi: 10.1007/s10637-014-0196-0. Epub 2014 Dec 12.
Clinical trial NCT04663984: Analysis of 2560 Theses
Official title: Publication Rates of Theses in the Field of Anesthesiology and Reanimation in Turkey; Analysis of 2563 Theses
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Publication Rates
Lead sponsor: Derince Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-12-11
Enrollment: 2563
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 2563 theses made between 2000 and 2018 using the keywords" anesthesiology and reanimation", full data of which can be accessed and allowed to be accessed by the authors over the internet.

Brief summary: Thesis publication rates in our country, according to research other medical branches; in psychiatry thesis % 37,4; Family Medicine, an increase of 0.9%; in emergency medicine and 7.3% in public health 1.5%; in microbiology %4,2; 5.7 percent in urology; brain surgery was 6.8%; general surgery 5%; 3.8% in eye diseases and surgery; ear, nose and throat diseases and surgery, in %4,2 as has been reported.


Eligibility criteria: Inclusion Criteria:

* the keywords" anesthesiology and reanimation"
* Made between 2000 and 2018,
* theses whose complete data can be accessed and allowed to be accessed by authors over the internet

Exclusion Criteria:

* theses whose complete data can be accessed and whose access is not allowed by the authors over the internet.

Primary outcomes:
measure: publication rate
timeFrame: 2 month
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: derince TRH
Study officials:
References:
citation: Erim BR, Petekkaya S. Retrospective Analysis of Psychiatry Specialization Theses Made Between 1981-2018 in Turkey. Turk Psikiyatri Derg. 2020 Spring;31(1):1-8. doi: 10.5080/u23877. English, Turkish.
citation: Sipahi OR, Caglayan Serin D, Pullukcu H, Tasbakan M, Koseli Ulu D, Yamazhan T, Arda B, Sipahi H, Ulusoy S. [Publication rates of Turkish medical specialty and doctorate theses on Medical Microbiology, Clinical Microbiology and Infectious Diseases disciplines in international journals]. Mikrobiyol Bul. 2014 Apr;48(2):341-5. doi: 10.5578/mb.7003. Turkish.
Clinical trial NCT02885584: Conventional Mechanical Ventilation and High Frequency Percussive Ventilation: Comparison of Their Effects on Alveolar Recruitment and Distension by CT-scan in Early ARDS Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: ARDS
Keywords: Mechanical ventilation
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2016-08-31
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: High frequency percussive ventilation (HFPV) is a high frequency ventilation mode in which high frequency pulses accumulate to generate a low frequency tidal volume at a controlled airway pressure. Previous studies have suggested a protective effect of HFPV on lung injury. The goal of our study is to compare, in early ARDS patients, the effects of conventional mechanical ventilation and of high frequency percussive ventilation on alveolar recruitment and distension evaluated by CT-scan


Eligibility criteria: Inclusion Criteria:

* Patient undergoing invasive ventilation for more than 24h
* ARDS patient

Exclusion Criteria:

* Pneumothorax drained or not
* Patient undergoing extracorporel mechanical oxygenation
* Patient who had a pneumonectomy partiel or total

Primary outcomes:
measure: Percent of patients exhibiting under HFPV an increase of at least 15% of normally aerated end-expiratory lung volume
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique-Hôpitaux de Marseille
Study officials:
affiliation: Assistance Publique-Hôpitaux de Marseille
name: Urielle DESALBRES
role: STUDY_DIRECTOR
affiliation: Assistance Publique-Hôpitaux de Marseille
name: Antoine ROCH, MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03129984: Mandibular Movement Test as a Screening Tool for Polysomnography Candidates
Official title: A Mandibular Movement Test as a Screening Tool for Polysomnography Candidates Among Patients With Sleep Apnea: a Retrospective Feasibility Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea Syndromes
Keywords: mandibular movements
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
Collaborators: name: nomics s.a.
First posted: 2017-04-26
Enrollment: 4231
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study is re-evaluating data provided by the Brizzy register in Belgium.

Brief summary: The primary objective of this study is to determine the technical failure and inconclusive test rates when using the Brizzy device for mandibular movement tracking.


Eligibility criteria: Inclusion Criteria:

* Patient included in the Brizzy register
* Mandibular movement test prescribed by practitioner
* Patient performed a mandibular movement test (ambulatory setting) using a magnetic sensor (Brizzy, Nomics, Liege, Belgium)

Exclusion Criteria:

* none

Primary outcomes:
measure: The exploitable data rate
timeFrame: Day 0 (retrospective cross-sectional study)
Secondary outcomes:
measure: Respiratory disturbance index based on mandibular movements
timeFrame: Day 0 (retrospective cross-sectional study)
measure: Minimal estimated total sleep time
timeFrame: Day 0 (retrospective cross-sectional study)
measure: ODI
timeFrame: Day 0 (retrospective cross-sectional study)
measure: Type of prescriber (qualitative)
timeFrame: Day 0 (retrospective cross-sectional study)
measure: Identification of reasons why a given test was unusable
timeFrame: Day 0 (retrospective cross-sectional study)
measure: age
timeFrame: Day 0 (retrospective cross-sectional study)
Other outcomes:
Locations:
Study officials:
affiliation: University Hospitals of Montpellier
name: Dany Jaffuel, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Rotty MC, Mallet JP, Borel JC, Suehs CM, Bourdin A, Molinari N, Jaffuel D. The feasibility of a mandibular movement test as a screening tool for polysomnography candidates. Eur Respir J. 2017 Nov 30;50(5):1701076. doi: 10.1183/13993003.01076-2017. Print 2017 Nov. No abstract available.
Clinical trial NCT04970784: Impact of a Dedicated Geriatric Sector on the Loss of Functional Autonomy at 1 Month for Patients Admitted to Emergencies and Non-hospitalised
Official title: Impact of a Dedicated Geriatric Sector on the Loss of Functional Autonomy at 1 Month for Patients Admitted to Emergencies and Non-hospitalised
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Health Services for the Aged
Emergency Service, Hospital
Ambulatory Care
Keywords: Elderly
Geriatric sector
Autonomy
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2021-07-21
Enrollment: 285
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly patients admitted to emergencies without hospitalization

Brief summary: Several studies have shown that going to the emergency room is a risk factor for loss of independence in the elderly. It has been shown that the period following an emergency room visit without hospitalization is a period of vulnerability for the elderly.

The functional decline, or loss of functional autonomy, of the elderly is associated with an increase in institutionalization, mortality and costs to society.

Studies have highlighted the risk factors for functional decline in the elderly, such as pre-existing functional and cognitive decline, undernutrition, but no model of care has yet prevented the risk of loss of autonomy after a stay in the emergency room.

A full and early geriatric assessment could prevent functional decline after the emergency room visit.

The primary objective of the study is to assess the impact of a dedicated geriatric sector on the functional decline at 1 month of patients admitted to emergencies without hospitalization by comparing an intervention group (patient having benefited from the geriatric sector) and a group witness ("classic" emergency patient).

The secondary objective is to evaluate the impact of this sector on the number of falls at home as well as the readmission rate within 1 month of going to the emergency room.


Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 75 years
* Emergency room consultation between 7:30 a.m. and 5:30 p.m.
* Relevant to the adult emergency department
* Return home after consultation

Exclusion Criteria:

* Age less than 75 years
* Arrival time between 5.30 p.m. and 7.30 a.m.
* Need to take care of unhooking
* Belonging to the short sector, versatile sector
* Patients hospitalized after consultation

Primary outcomes:
measure: Change of functional decline at 1 month, measured by the Katz index, Activities of Daily Living (ADL)
timeFrame: At Baseline (admission to ermergencies) and 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Contamine-sur-Arve
country: France
facility: Centre Hospitalier Alpes Léman, service des urgences
Study officials:
affiliation: Centre Hospitalier Alpes Léman, service des urgences
name: Jessica POINTURIER
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01394484: Dairy Foods Compared to Dietary Supplements and Bone Health
Official title: Milk and Yogurt vs. Calcium and Vitamin D Supplements for Bone Health of Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoporosis
Bone Loss
Osteopenia
Lead sponsor: USDA, Western Human Nutrition Research Center
Sponsor class: FED
Collaborators: name: Dairy Management Inc.
First posted: 2011-07-14
Enrollment: 12
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Does the consumption of dairy foods reduce the rate of bone loss in older women more than calcium and vitamin D supplements.

Detailed description: Research indicates that bone health is dependent on multiple nutrients, not just calcium and vitamin D, leading to the conclusion that calcium from sources that include other bone enhancing nutrients may be more effective in maintaining bone integrity than calcium and vitamin D supplements. Several studies have examined the effects of calcium intake from dairy foods on different indicators of bone health. Reducing the rate of bone loss in postmenopausal women can reduce the risk of osteoporosis related fractures. Therefore we propose to study the effectiveness of 4 servings of milk and yogurt per day for 42 days compared to calcium and vitamin D supplements for 42 days to reduce calcium loss from the skeleton in post menopausal women. Postmenopausal women, approximately 50-65 years of age, will be studied. Each volunteer will receive both interventions in a cross-over design, in random order, separated by a 42 day washout period.

Eligibility criteria: Inclusion Criteria:

* Minimum 24 months since last menses
* No hormone therapy in the past 12 months
* Weight stable for the past 3 months
* Bone density T score -1.7 to 0.0
* No more than two dairy servings per day
* No history of inflammatory disorders
* No history of non-traumatic bone fracture
* No supplement use or willing to discontinue
* No lactose intolerance
* Willing to consume milk and yogurt

Exclusion Criteria:

* Less than 24 months since last menses
* Use of hormone therapy in past yr
* \> 5 pound weight change in past 3 months
* Osteoporosis
* Regular \>2 servings/d of dairy
* Auto-immune/inflammatory disorders
* History of non-traumatic bone fracture
* Unwilling to discontinue supplements
* Lactose intolerance
* Unwilling to eat yogurt or drink milk

Primary outcomes:
measure: Ratio of 41Ca/40Ca excreted in urine
timeFrame: Days 0, 90, 120, 150, 180, 187, 194, 201, 208, 215, 222, 229, 236, 243, 250, 257, 264,271, 278, 285, 292, 299, and 306 of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Davis
country: United States
facility: Western Human Nutrition Research Center
state: California
Study officials:
affiliation: WHNRC, ARS, University of California Davis
name: Marta Van Loan, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: USDA, ARS, WHNRC
name: Marjorie Garrod, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT03815084: A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Official title: Clinical Study on the Safety and Efficacy of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Solid Tumor
Lead sponsor: Allife Medical Science and Technology Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: The First People's Hospital of Yunan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital
name: Henan Provincial People's Hospital
name: Beijing Hospital
First posted: 2019-01-24
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors


Eligibility criteria: Inclusion Criteria:

1. Previously receiving ≥ first-line regimen chemotherapy;
2. Age over 3 years old and less than 14 years old;
3. The expected survival period is more than 3 months;
4. ECOG≤2;
5. Vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ECG; blood oxygen saturation ≥ 90%; creatinine clearance calculated by Cockcroft-Gault formula ≥ 40ml/min; ALT and AST ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg / dl;
6. Blood routine: Hgb≥80g/L, ANC≥1×109/L, PLT≥50×109/L; There are measurable target lesions.

Exclusion Criteria:

1. Liver and kidney function:

   * Total bilirubin \> 2 x ULN (Gilbert syndrome \> 3 x ULN)
   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \> 3 × ULN
   * Serum creatinine clearance \>60mL/min
2. Serological examination:

   * Absolute neutrophil count (ANC) \<0.75x109/L
   * Platelet count (PLT) \<50x109/L
3. Active hepatitis B (HBV-DNA \> 1000 copies / ml), hepatitis C, or uncontrolled infection;
4. The number of days of chemotherapy medication and the administration of hormones below 5mg is ≤3, and the number of days of withdrawal of hormones greater than 5mg is ≤5;
5. Active CNS disease (tumor cells in CSF);
6. Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
7. creatinine \> 1.5 times the upper limit of normal or ALT / AST \> 3 times the upper limit of normal or bilirubin \> 2 times the upper limit of normal;
8. The New York Heart Association (NYHA) is classified as Level III or higher;
9. Uncontrolled diabetes;
10. With other uncontrolled diseases, the investigator believes that it is not suitable for joining;
11. Any situation that the investigator believes may increase the risk of the subject or interfere with the test results.

Primary outcomes:
measure: occurrence of treatment related adverse events
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: